<DOC>
	<DOCNO>NCT01494584</DOCNO>
	<brief_summary>This open-label study evaluate pharmacokinetics , safety tolerability ezogabine/retigabine subject age 12 year less 18 year uncontrolled partial onset seizures Lennos-Gastaut syndrome .</brief_summary>
	<brief_title>Study Pediatric Subjects With Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Ezogabine</mesh_term>
	<criteria>Between 12 18 year age . Diagnosis uncontrolled partial onset seizure ( without secondarily generalize seizure ) LennoxGastaut syndrome . Taking one three antiepileptic drug . Able swallow tablet . Females must : ( 1 ) Nonchildbearing potential ( 2 ) Childbearing potential agrees use acceptable contraception . Epilepsy secondary progressive cerebral disease , tumor progressive neurodegenerative disease . History status epilepticus last six month . Currently treat felbamate treat vigabatrin within past 6 month . Following ketogenic diet . Suicidal intent history suicide attempt last 2 year . Elevated liver enzyme abnormal kidney function . Current disturbance micturition know urinary obstruction . History vesicoureteric reflux . Abnormal postvoid residual bladder ultrasound . Urinary retention and/or require urinary catheterization precede 6 month . Abnormal urine sample screening/.baseline . Abnormal blood sample screen . Clinically significant arrhythmia . Abnormal ECG screen . BMI low 10th percentile age gender subject weigh less 30kg .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>